X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
Cowen and Stifel are acting as joint book-running managers and
representatives of the underwriters for the offering.
The offering is being made only by means of a written prospectus and
related prospectus supplement forming part of a shelf registration
statement on Form S-3 that was filed with the
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended. The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements include statements regarding the completion
of the proposed public offering. These statements are subject to various
risks and uncertainties, actual results could differ materially from
those projected and X4 cautions investors not to place undue reliance on
the forward-looking statements in this press release. These risks and
uncertainties include, without limitation, risks and uncertainties
related to market conditions and satisfaction of customary closing
conditions related to the public offering. There can be no assurance
that X4 will be able to complete the public offering on the anticipated
terms and on the anticipated closing date, or at all. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed or
implied by any forward-looking statements contained in this press
release, including, without limitation, the risks and uncertainties
described in the section entitled “Risk Factors” in X4’s preliminary
prospectus supplement related to the proposed offering filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190412005261/en/
Source:
Investors:
Stephanie Carrington
Westwicke, an ICR
company
646-277-1282
Stephanie.Carrington@icrinc.com
Media:
Darcie
Robinson
Westwicke, an ICR company
203-919-7905
Darcie.robinson@icrinc.com